COVID-19

Central Drugs Standard Control Organisation has approved phase II trials of Bharat Biotech's vaccine candidate Covaxin. After satisfactory results of Phase I clinical trial, DCGI has given permission for phase II trials of Covaxin, which is developed by Bharat biotech in alliance with the ICMR - National Institute of Virology.

Designing a vaccine starts with finding the right ingredients. Every infectious agent has molecules, called antigens, that the immune system could potentially recognize and attack. So scientists must carefully consider which antigens should go into a vaccine.

The use of antibiotics in people with COVID-19 could result in increased resistance to the drugs' benefits among the wider population, a new study suggests.